Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Cannara Biotech's 3-Year RORE % for the quarter that ended in Feb. 2026 was 12.89%.
The industry rank for Cannara Biotech's 3-Year RORE % or its related term are showing as below:
LOVFF's 3-Year RORE % is ranked better than 61.47% of 937
companies
in the Drug Manufacturers industry
Industry Median: 3.09
vs LOVFF: 12.89
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Cannara Biotech 3-Year RORE % Related Terms
Cannara Biotech 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Feb. 2026 and 3-year before.
Cannara Biotech (LOVFF) has a 3-Year RORE % of 12.89 as of Feb. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Cannara Biotech and its competitors. According to the industry distribution chart, Cannara Biotech ranks #361 out of 937 companies in the Drug Manufacturers industry, placing it in the top 38.5%.
Is Cannara Biotech's 3-Year RORE % too high?
Cannara Biotech's current 3-Year RORE % is 12.89. The Drug Manufacturers industry median 3-Year RORE % is 3.09. Cannara Biotech's value of 12.89 is 317.2% above this industry median. Based on the distribution chart, Cannara Biotech ranks #361 out of 937 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cannara Biotech has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #361 out of 937 companies for 3-Year RORE %. This puts Cannara Biotech in the upper half of its industry. The industry median 3-Year RORE % is 3.09. Cannara Biotech's value of 12.89 is 317.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.09, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current 3-Year RORE % of 12.89 is 317.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current 3-Year RORE % is 12.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.17, compared to a current price of $1.29 — trading 10.3% above its estimated fair value. The current 3-Year RORE % is 12.89 and 317.2% above the Drug Manufacturers industry median of 3.09. Cannara Biotech's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current 3-Year RORE % is 12.89 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.29 is trading 10.3% above its estimated GF Value™ of $1.17.
GuruFocus considers Cannara Biotech to be Fairly Valued.
Key valuation signals for LOVFF:
3-Year RORE %: 12.89
GF Value™: $1.17 vs. price of $1.29 (10.3% above fair value)
Industry Position: 317.2% above the Drug Manufacturers median (#361 of 937)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
87GF Score
Get the complete analysis for LOVFF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
